|

Ramucirumab Clinical Trials

19 actively recruiting trials across 14 locations

Also known as: Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, CYRAMZA®, Cyramza, IMC 1121B, IMC-1121B +5 more

Pipeline

Phase 1: 3Phase 2: 11Phase 1/2: 3Phase 2/3: 2

Top Sponsors

  • SWOG Cancer Research Network4
  • AstraZeneca3
  • Memorial Sloan Kettering Cancer Center2
  • Toray Industries, Inc1
  • Taiho Pharmaceutical Co., Ltd.1

Indications

  • Cancer19
  • Lung Cancer9
  • Non Small Cell Lung Cancer5
  • Metastatic Gastric Adenocarcinoma4
  • Recurrent Lung Non-Small Cell Carcinoma3

Birmingham, Alabama2 trials

Daphne, Alabama2 trials

Anchorage, Alaska2 trials

Duarte, California2 trials

Other1 trial

Phoenix, Arizona1 trial

Tucson, Arizona1 trial

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)

Phase 1/2

Little Rock, Arkansas1 trial

Los Angeles, California1 trial

Orange, California1 trial

Santa Monica, California1 trial

Rochester, Minnesota1 trial

Basking Ridge, New Jersey1 trial

Middletown, New Jersey1 trial

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Phase 1/2

Philadelphia, Pennsylvania1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.